Aclaris Therapeutics Inc.
| NASDAQ: ACRS | Healthcare / Biotechnology / USA |
| 28.96 | -0.1300 | -0.45% | Vol 400.73K | 1Y Perf 2 417.39% |
| Apr 9th, 2021 16:00 DELAYED |
| BID | 24.50 | ASK | 30.45 | ||
| Open | 29.06 | Previous Close | 29.09 | ||
| Pre-Market | - | After-Market | 28.96 | ||
| - - | - -% |
| Target Price | 26.67 | Analyst Rating | Strong Buy 1.40 | |
| Potential % | -7.91 | Finscreener Ranking | ★★★ 50.00 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★+ 48.60 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ 48.13 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 1.50B | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 95.16 | Earnings Date | 6th May 2021 |
Today's Price Range 28.6029.64 | 52W Range 1.0230.38 | 5 Year PE Ratio Range -9.40-2.00 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 9.28% | ||
| 1 Month | 26.91% | ||
| 3 Months | 367.85% | ||
| 6 Months | 509.68% | ||
| 1 Year | 2 417.39% | ||
| 3 Years | 66.92% | ||
| 5 Years | 43.65% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -61.54 | |||
ROE last 12 Months | -89.68 | |||
ROA (5Y Avg) | -110.98 | |||
ROA last 12 Months | -57.38 | |||
ROC (5Y Avg) | -63.14 | |||
ROC last 12 Months | -67.26 | |||
Return on invested Capital Q | -26.12 | |||
Return on invested Capital Y | -78.42 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 6.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -22.10 | ||||
| 34.67 | ||||
| 286.33 | ||||
| - | ||||
| -42.70 | ||||
| -0.91 | ||||
| 44.97 | ||||
| 0.73 | ||||
| 1.33B | ||||
| Forward PE | -19.92 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.70 | ||||
| 3.90 | ||||
| 0.22 | ||||
| 0.30 | ||||
| - | ||||
| Leverage Ratio | 1.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 11.30 | ||||
| -915.50 | ||||
| -880.60 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.08M | ||||
| 0.10 | ||||
| 31.91 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.28 | -0.31 | -10.71 |
| Q03 2020 | -0.29 | -0.25 | 13.79 |
| Q02 2020 | -0.34 | -0.28 | 17.65 |
| Q01 2020 | -0.29 | -0.36 | -24.14 |
| Q04 2019 | -0.34 | -0.46 | -35.29 |
| Q03 2019 | -0.54 | -0.56 | -3.70 |
| Q02 2019 | -0.77 | -0.72 | 6.49 |
| Q01 2019 | -0.80 | -0.91 | -13.75 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.26 | 72.04 | Positive |
| 6/2021 QR | -0.25 | 70.59 | Positive |
| 12/2021 FY | -1.12 | - | - |
| 12/2022 FY | -1.33 | - | - |
| Next Report Date | 6th May 2021 |
| Estimated EPS Next Report | -0.26 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 400.73K |
| Shares Outstanding | 51.80M |
| Trades Count | 4.62K |
| Dollar Volume | 10.91M |
| Avg. Volume | 2.81M |
| Avg. Weekly Volume | 621.16K |
| Avg. Monthly Volume | 754.81K |
| Avg. Quarterly Volume | 2.99M |
Aclaris Therapeutics Inc. (NASDAQ: ACRS) stock closed at 28.96 per share at the end of the most recent trading day (a -0.45% change compared to the prior day closing price) with a volume of 416.13K shares and market capitalization of 1.50B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 60 people. Aclaris Therapeutics Inc. CEO is Neal Walker.
The one-year performance of Aclaris Therapeutics Inc. stock is 2417.39%, while year-to-date (YTD) performance is 347.6%. ACRS stock has a five-year performance of 43.65%. Its 52-week range is between 1.02 and 30.38, which gives ACRS stock a 52-week price range ratio of 95.16%
Aclaris Therapeutics Inc. currently has a PE ratio of -22.10, a price-to-book (PB) ratio of 34.67, a price-to-sale (PS) ratio of 286.33, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -57.38%, a ROC of -67.26% and a ROE of -89.68%. The company’s profit margin is -%, its EBITDA margin is -880.60%, and its revenue ttm is $5.08 Million , which makes it $0.10 revenue per share.
Of the last four earnings reports from Aclaris Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.26 for the next earnings report. Aclaris Therapeutics Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Aclaris Therapeutics Inc. is Strong Buy (1.4), with a target price of $26.67, which is -7.91% compared to the current price. The earnings rating for Aclaris Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aclaris Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aclaris Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 31.35, ATR14 : 2.06, CCI20 : 0.35, Chaikin Money Flow : 0.05, MACD : 1.18, Money Flow Index : 57.94, ROC : -2.43, RSI : 58.07, STOCH (14,3) : 53.92, STOCH RSI : 0.37, UO : 50.56, Williams %R : -46.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aclaris Therapeutics Inc. in the last 12-months were: Anand Mehra (Option Excercise at a value of $268 298), Andrew Kenneth Williams Powell (Option Excercise at a value of $0), Andrew N. Schiff (Option Excercise at a value of $0), Bryan M. Reasons (Option Excercise at a value of $0), Christopher Molineaux (Option Excercise at a value of $0), David N. Gordon (Option Excercise at a value of $0), Frank Ruffo (Option Excercise at a value of $0), Kamil Ali-Jackson (Option Excercise at a value of $0), Neal Walker (Option Excercise at a value of $0), William D. Humphries (Option Excercise at a value of $0)
Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.
CEO: Neal Walker
Telephone: +1 484 324-7933
Address: 640 Lee Road, Wayne 19087, PA, US
Number of employees: 60
